(before ages 75, 65, and 55) cancer mortality and hospitalization, by estimating difference-in-differences models based on … longitudinal, cancer-site-level data on about 30 cancer sites. The estimates indicate that cancer sites about which more research …-2013, controlling for the change in the number of people diagnosed. Cancer sites for which more non-research-supported articles were …

harsh. Part of the long-run increase in 5-year cancer survival rates is due to improved prevention, screening, or therapy …Previous investigators argued that increasing 5-year survival for cancer patients should not be taken as evidence of … improved prevention, screening, or therapy, because they found little correlation between the change in 5-year survival for a …

avoidance as the sole criterion. We find that, by standards of OECD countries, the US does well in terms of screening for cancer …, survival rates from cancer, survival rates after heart attacks and strokes, and medication of individuals with high levels of … blood pressure or cholesterol. We consider in greater depth mortality from prostate cancer and breast cancer, diseases for …

2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally …

uninsured women with breast cancer, we compared insured and uninsured women treated in a safety net setting. Controlling for … that, despite the safety net system, uninsured women with breast cancer are likely to require more costly treatment and to … have worse outcomes, relative to insured women with breast cancer …

recommendation. We explore this distinction in the context of recommendations that breast cancer screening start at age 40. The raw … data suggest that responders to the age 40 recommendation have less cancer than do women who self-select into screening at … recommendation also have less cancer than women who never screen, suggesting that the benefits of recommending early screening are …

. These treatments promise to dramatically raise durable survival rates for a growing number of cancer patients but are often … immunotherapy for melanoma patients. Extrapolating to 17 other cancer sites, we estimate the insurance sector's benefit to equal $6 …

paper analyzes the influence of physician investigators who lead clinical trials for new cancer drugs. By comparing … diffusion patterns across 21 new cancer drugs, we separate correlated regional demand for new technology from information …